Stay up to date on the latest in health tech, digital health and health AI news with this weekly brief. Read below for news from the week of Oct. 26 to 30.

Doximity launched DoseCheck, a new safety feature within Doximity Ask designed to catch unsafe or incorrect medication dosing recommendations generated by artificial intelligence.

Rather than relying on an LLM to double-check another LLM, DoseCheck adds a deterministic, rule-based verification layer, checking AI-generated dosing claims against structured information including FDA labeling and professional guidelines, the company said. By checking against FDA labeling and professional guidelines, DoseCheck increases accuracy to more than 99%, the company claims.

Doximity tested nine widely used AI models with more than 8,000 dosing questions based on real physician queries. At least 2.3% of dosing claims made by these models were wrong, and 43.8% of detected errors were serious or potentially lethal.

According to the analysis, common sources of errors include dosing newer drugs, failing to account for patient-specific factors such as kidney function, age, weight and medical history, and mistakes involving units, decimal points or drugs with similar names.

"AI is probabilistic. Drug dosing can’t be," said Louis-Antoine Mullie, M.D., chief AI researcher at Doximity. "DoseCheck doesn’t ask a language model to grade its own homework. It checks dosing claims against a structured, authoritative database, so physicians get the same verified dosing answer every time."

DoseCheck is free and has been rolled out to all Doximity Ask users across mobile and desktop.

Health and wellness platform Hims & Hers plans to launch a peptides specialty after the federal government signaled it will allow compounding pharmacies to manufacture six peptides temporarily.

Source link